Skip to main content
AAN.com

Abstract

Objective: To assess the diagnostic accuracy of flow cytometric immunophenotyping in comparison with classic cytomorphology for diagnosing CNS localizations of hematologic malignancies, and to evaluate the implications of CSF pleocytosis and protein content in this context.
Methods: We reviewed the results of diagnostic evaluations of all CSF samples analyzed for localization of a hematologic malignancy between 2001 and 2004 at our center.
Results: A total of 1,054 samples from 219 patients were available for analysis. Sixty patients had a CSF localization diagnosed by positive flow cytometry, cytomorphology, or both. The first sample was positive by flow cytometry in 44 (73%) patients, by cytomorphology in 19 (32%). Four first samples were positive by cytomorphology but negative by flow cytometry. Patients with positive cytomorphology had more frequent clinical symptomatology (95% vs 58%) and CSF pleocytosis (84% vs 25%), and tended to a poorer progression-free survival than patients with positive flow cytometry only. OR for CNS localization in case of CSF pleocytosis was 10.1 (95% CI 4.9 to 20.8); OR for CNS localization in case of elevated protein content was 2.9 (95% CI 1.5 to 5.4). Nevertheless, 26 of 137 (19%) patients with normal cell count and protein concentration had a CNS localization.
Conclusions: The diagnostic value of flow cytometry is more than twice that of cytomorphology. However, cytomorphologic examination of the CSF has additional diagnostic and possibly prognostic value, and should still be performed in conjunction with flow cytometry.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979;29:1369–1375.
2.
Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51–57.
3.
Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neuro-oncol 1990;9:225–229.
4.
Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759–772.
5.
Clinical and Laboratory Standards Institute. Clinical flow cytometric analysis of neoplastic hematolymphoid cells; approved guideline, 2nd edition. CLSI document H43-A2 [ISBN 1-56238-000-0]. Wayne, PA: CLSI, 2006.
6.
Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Semin Hematol 2001;38:111–123.
7.
Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005;105:496–502.
8.
Nowakowski GS, Call TG, Morice WG, Kurtin PJ, Cook RJ, Zent CS. Clinical significance of monoclonal B cells in cerebrospinal fluid. Cytometry B Clin Cytometry 2005;63:23–27.
9.
Finn WG, Peterson LC, James C, Goolsby CL. Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. Am J Clin Pathol 1998;110:341–346.
10.
French CA, Dorfman DM, Shaheen G, Cibas ES. Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol 2000;23:369–374.
11.
Subira D, Castanon S, Roman A, et al. Flow cytometry and the study of central nervous disease in patients with acute leukaemia. Br J Haematol 2001;112:381–384.
12.
Peter A. Cytological changes in the cerebrospinal fluid following intrathecal methotrexate treatment. I. Observations in adult meningeal leukemia. Confin Neurol 1974;36:186–196.
13.
Kraan J, Gratama JW, Keeney M, D'Hautcourt JL. Setting up and calibration of a flow cytometer for multicolor immunophenotyping. J Biol Regul Homeost Agents 2003;17:223–233.
14.
Roma AA, Garcia A, Avagnina A, Rescia C, Elsner B. Lymphoid and myeloid neoplasms involving cerebrospinal fluid: comparison of morphologic examination and immunophenotyping by flow cytometry. Diagn Cytopathol 2002;27:271–275.
15.
Subira D, Gorgolas M, Castanon S, et al. Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med 2005;6:21–26.
16.
Schistine M, Filie AC, Wilson W, Stetler-Stevenson M, Abati A. Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious. Cancer (Cancer Cytopathol) 2006;108:157–162.

Information & Authors

Information

Published In

Neurology®
Volume 68Number 20May 15, 2007
Pages: 1674-1679
PubMed: 17502548

Publication History

Published online: May 14, 2007
Published in print: May 15, 2007

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

J.E.C. Bromberg, MD
From the Departments of Neuro-Oncology (J.E.C.B., P.S.S., M.J.v.d.B.), Hematology (D.A.B., M.v.V.), Medical Oncology (J.K., J.W.G.), Clinical Chemistry (G.B.), and Trials and Statistics (B.v.d.H.), Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
D. A. Breems, MD, PhD
From the Departments of Neuro-Oncology (J.E.C.B., P.S.S., M.J.v.d.B.), Hematology (D.A.B., M.v.V.), Medical Oncology (J.K., J.W.G.), Clinical Chemistry (G.B.), and Trials and Statistics (B.v.d.H.), Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
J. Kraan, BSc
From the Departments of Neuro-Oncology (J.E.C.B., P.S.S., M.J.v.d.B.), Hematology (D.A.B., M.v.V.), Medical Oncology (J.K., J.W.G.), Clinical Chemistry (G.B.), and Trials and Statistics (B.v.d.H.), Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
G. Bikker
From the Departments of Neuro-Oncology (J.E.C.B., P.S.S., M.J.v.d.B.), Hematology (D.A.B., M.v.V.), Medical Oncology (J.K., J.W.G.), Clinical Chemistry (G.B.), and Trials and Statistics (B.v.d.H.), Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
B. van der Holt, MSc
From the Departments of Neuro-Oncology (J.E.C.B., P.S.S., M.J.v.d.B.), Hematology (D.A.B., M.v.V.), Medical Oncology (J.K., J.W.G.), Clinical Chemistry (G.B.), and Trials and Statistics (B.v.d.H.), Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
P. Sillevis Smitt, MD, PhD
From the Departments of Neuro-Oncology (J.E.C.B., P.S.S., M.J.v.d.B.), Hematology (D.A.B., M.v.V.), Medical Oncology (J.K., J.W.G.), Clinical Chemistry (G.B.), and Trials and Statistics (B.v.d.H.), Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
M. J. van den Bent, MD
From the Departments of Neuro-Oncology (J.E.C.B., P.S.S., M.J.v.d.B.), Hematology (D.A.B., M.v.V.), Medical Oncology (J.K., J.W.G.), Clinical Chemistry (G.B.), and Trials and Statistics (B.v.d.H.), Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
M. van't Veer, MD, PhD
From the Departments of Neuro-Oncology (J.E.C.B., P.S.S., M.J.v.d.B.), Hematology (D.A.B., M.v.V.), Medical Oncology (J.K., J.W.G.), Clinical Chemistry (G.B.), and Trials and Statistics (B.v.d.H.), Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
J. W. Gratama, MD, PhD
From the Departments of Neuro-Oncology (J.E.C.B., P.S.S., M.J.v.d.B.), Hematology (D.A.B., M.v.V.), Medical Oncology (J.K., J.W.G.), Clinical Chemistry (G.B.), and Trials and Statistics (B.v.d.H.), Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.

Notes

Address correspondence and reprint requests to Dr. Jacoline E.C. Bromberg, Department of Neuro-Oncology, Daniel den Hoed Cancer Center, Erasmus MC, University Medical Center Rotterdam, PO Box 5201, 3008 AE Rotterdam, the Netherlands [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Primary Leptomeningeal Lymphoma in HIV-infected Patients Presented with Subacute Meningitis, Journal of Clinical Infectious Disease Society, 2, 3, (138-140), (2024).https://doi.org/10.4103/CIDS.CIDS_5_24
    Crossref
  2. Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma, Journal of Clinical Medicine, 13, 16, (4745), (2024).https://doi.org/10.3390/jcm13164745
    Crossref
  3. Diagnostic, Pathologic, and Therapeutic Considerations for Primary CNS Lymphoma, JCO Oncology Practice, 20, 2, (195-202), (2024).https://doi.org/10.1200/OP.23.00294
    Crossref
  4. Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers, BMC Neurology, 24, 1, (2024).https://doi.org/10.1186/s12883-024-03761-6
    Crossref
  5. Not everything is ischemic optic neuropathy, Survey of Ophthalmology, 69, 6, (984-989), (2024).https://doi.org/10.1016/j.survophthal.2024.05.005
    Crossref
  6. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm, Clinical Lymphoma Myeloma and Leukemia, 24, 4, (e130-e137), (2024).https://doi.org/10.1016/j.clml.2023.12.010
    Crossref
  7. Patterns and prognostic impact of CNS infiltration in adults with newly diagnosed acute lymphoblastic leukemia, Annals of Hematology, 103, 6, (2033-2039), (2024).https://doi.org/10.1007/s00277-023-05609-4
    Crossref
  8. Flow Cytometry Applications in the Diagnosis and Classification of Aggressive B-Cell Lymphoma, Precision Molecular Pathology of Aggressive B-Cell Lymphomas, (125-142), (2024).https://doi.org/10.1007/978-3-031-46842-1_8
    Crossref
  9. Incidence, risk factors, and outcome of asymptomatic central nervous system involvement in adult patients with acute myeloid leukemia, Hematological Oncology, 42, 2, (2024).https://doi.org/10.1002/hon.3253
    Crossref
  10. Lymphoma of Nervous System or the Great Imitator in Neurology, EMJ Neurology, (129-135), (2023).https://doi.org/10.33590/emjneurol/10306735
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share